HanchorBio Announces HCB301 Oral Presentation and HCB101 Best Poster Selection at KSMO 2026
Three abstracts accepted across HCB101 and HCB301,
including the gastric cancer Best Poster Presentation Award and Poster Discussion
TAIPEI, SHANGHAI, and SAN FRANCISCO — August 19, 2026 — HanchorBio, Inc. (TWSE: 7827), a global clinical-stage biotechnology company developing next-generation immunotherapies for oncology and immune-mediated diseases, today announced that three abstracts featuring its clinical-stage programs HCB101 and HCB301 have been accepted for presentation at KSMO 2026—the 19th Annual Meeting of the Korean Society of Medical Oncology and 2026 International Conference—held in conjunction with the 14th International Conference of the Federation of Asian Clinical Oncology (FACO), taking place September 2–4, 2026, in Seoul, Korea.
The presentations include two posters on HCB101 clinical development in gastric cancer (GC) and head and neck squamous cell carcinoma (HNSCC), as well as an oral presentation of first-in-human clinical data for HCB301, HanchorBio’s tri-specific SIRPα–PD-L1–TGFβ fusion protein.
The HCB101 gastric cancer abstract has also been selected for the KSMO 2026 Best Poster Presentation Award and a Poster Discussion presentation. According to KSMO, only outstanding abstracts were selected for the Poster Discussion sessions.
“We are pleased to have three clinical presentations selected for KSMO 2026 and FACO across two programs from our FBDB™ platform,” said Scott Liu, PhD, Founder, Chairman, and CEO of HanchorBio. “HCB101 and HCB301 represent our innovative approaches to overcoming immune resistance, from activating macrophage-mediated antitumor immunity to integrating and synergizing multiple immune pathways within a single therapeutic molecule. We look forward to sharing our progress with the oncology community in Seoul.”
Alvin Luk, Ph.D., M.B.A., C.C.R.A., President and Chief Medical Officer (Group) & CEO (USA) of HanchorBio, will deliver the HCB301 oral presentation.
HanchorBio Presentations at KSMO 2026 / FACO
- HCB101 — Gastric Cancer
Preliminary Antitumor Activity of HCB101 (SIRPα-Fc Fusion Protein)-Based Combination Therapy in Advanced Gastric Cancer- Presentation: Best Poster Presentation Award / Poster Discussion (In-Person Presentation)
- Date:September 3, 2026
- Poster Discussion Session:14:50–15:20 KST
- Presentation Format:4-minute presentation + 2-minute real-time Q&A
- Presentation Code/Location: PD01/Carnation Room (5 Floor)
- HCB101 — Head and Neck Squamous Cell Carcinoma
HCB101 in HNSCC: Early Clinical Evidence Supporting PD-1- and EGFR-Directed Combination Strategies- Presentation:Poster
- Date:September 3, 2026
- HCB301 — First-in-Human Phase 1 Study
Coordinated SIRPα-PD-L1-TGFβ Modulation with HCB301: Early Safety and Disease Control in a First-in-Human Phase 1 Study- Presentation:Oral Presentation (In-Person Presentation)
- Presenter:Alvin Luk, Ph.D., M.B.A., C.C.R.A.
- Date:September 4, 2026
- Session:14:40–15:40 KST
- Presentation Code/Location: OP02-1/Room D (Grand Ballroom)
- KSMO 2026 Best Poster Presentation Award Ceremony
- Date:September 4, 2026
- Time: 16:10–16:30 KST/Room C (Grand Ballroom)
“KSMO and FACO bring together an important community of oncologists and clinical investigators from across Asia and internationally,” said Dr. Luk. “The selection of HCB301 for oral presentation, together with two HCB101 presentations and the recognition of our gastric cancer work through the Best Poster Presentation Award, gives us an opportunity to present the growing clinical breadth of the FBDB™ platform. We look forward to discussing these programs and their potential to expand the therapeutic possibilities of cancer immunotherapy.”
The KSMO presentations will highlight HCB101’s clinical development in gastric cancer and HNSCC, including combination strategies with established anticancer therapies, as well as first-in-human clinical experience with HCB301 and its coordinated targeting of innate immune suppression, adaptive immune checkpoint signaling, and TGFβ-mediated immune exclusion.
Additional clinical data from the presentations will be shared following their presentation at KSMO 2026.
About HCB101
HCB101 is an investigational engineered SIRPα–IgG4 Fc fusion protein developed using HanchorBio’s proprietary FBDB™ platform. HCB101 blocks CD47–SIRPα signaling and is designed to enhance macrophage-mediated antitumor immunity. It is being evaluated as monotherapy (NCT05892718) and in combinations (NCT06771622) across solid and hematologic malignancies. HCB101 has received U.S. FDA Orphan Drug Designation for gastric cancer.
About HCB301
HCB301 is an investigational tri-specific SIRPα–PD-L1–TGFβ IgG4 fusion protein designed to coordinately modulate innate immunity, adaptive immunity, and TGFβ-mediated immune exclusion within a single therapeutic molecule. It is being evaluated in the ongoing first-in-human Phase 1 HCB301-101 study (NCT06487624).
About HanchorBio
HanchorBio (TWSE: 7827) is a global clinical-stage biotechnology company developing next-generation immunotherapies for oncology and immune-mediated diseases. Its proprietary Fc-Based Designer Biologics (FBDB™) platform enables the engineering of multifunctional biologics designed to coordinately modulate complementary immune pathways.
HanchorBio’s pipeline includes clinical-stage programs HCB101 (a SIRPα-based innate immune checkpoint program) and HCB301 (a trispecific immunotherapy targeting SIRPα, PD-L1, and TGF-β biology), as well as next-generation programs including HCB303 and additional candidates across oncology and immune-mediated diseases. With operations in Taiwan, China, and the United States, HanchorBio integrates therapeutic engineering, translational science, clinical development, and global regulatory execution. For more information, please visit HanchorBio.com.
Forward-Looking Statements
This press release contains forward-looking statements, including statements regarding the development of HCB303, the timing and potential submission of an IND, initiation and design of future clinical studies, potential therapeutic characteristics and mechanisms of HCB303, development of HanchorBio’s pipeline, and the capabilities and potential of the FBDB™ platform. These statements are based on current expectations and assumptions and involve risks and uncertainties that could cause actual results to differ materially from those described. Regulatory feedback does not constitute approval of an IND or assurance that clinical development will proceed as planned. HanchorBio undertakes no obligation to update forward-looking statements except as required by applicable law.